by Jim Gearhart

Week in Review (February 27, 2015)

QIRB-jim-gearhart-blog2Happy Friday! February 28 is Rare Disease Day, which the European Organization of Rare Diseases started eight years ago. This year, the FDA used the occasion to comment on its program for orphan drugs, and Lilly’s blog COI reflected on learning from victims of rare diseases.

Here are some news highlights from the world of clinical research:

The New York Times examined how genetic markers have led to researching the treatment of multiple types of cancer at once.

The European Medicines Agency continued to debate expanding requirements for reporting clinical study data.

The FDA revised its prohibition against 23andMe providing health information based on home-based genetic test kits. Biopharmdive looked at how clinical trials helped 23andMe change the FDA’s mind.

A clinical trial showed that introducing peanuts into babies’ diets safely helped limit allergies.

A Toronto newspaper withdrew an article that alleged side effects of a vaccine against the cancer-causing human papillomavirus (HPV).

The Federal Trade Commission (not the FDA, interestingly) prosecuted smartphone app developers for false claims about making medical diagnoses.

The Wall Street Journal looked at how some hospitals are using new technologies to introduce remote health monitoring.

The first Apple Watch will not include as many health-monitoring features as originally claimed. And, Apple meets with Mexican regulators this month ahead of the debut of its smart watches.

Pfizer announced that it is planning layoffs in R&D to reorient priorities.

And, for Fun:

The NIH has a new game, an app for your smart phone. Try your thumbs at being a bio-engineer.

Tags: , , , ,